Rheumatoid Arthritis

Patients with high RF concentration treated with CZP were more likely to achieve DAS28-CRP low disease activity at week 104 than those treated with adalimumab.

The MTX + HCQ group had a higher, but not statistically significant, incidence rate of TEAEs than the monotherapy group.

Panelists discuss advanced treatment options for rheumatoid arthritis, focusing on the SELECT-COMPARE trial's head-to-head data of upadacitinib versus adalimumab, the use of upadacitinib in active RA refractory to biologics (SELECT-BEYOND trial), and the remission rates of upadacitinib compared to abatacept (SELECT-CHOICE trial).

Investigators noted that a formal independent validation cohort needs to be developed in order to realize the full potential of the human model.

Lengths of stay, total cost, and hospital mortality rates were similar between patients with and without rheumatoid arthritis.

Investigators also found that bDMARDs were used more often by patients with early-onset rheumatoid arthritis than by patients with late-onset.

A panel of medical experts explore how to evaluate and adjust rheumatoid arthritis treatment by adhering to ACR guidelines for conventional synthetic DMARDs and advanced therapies, focusing on optimizing patient care and treatment outcomes.

Medical experts explore how patient perceptions of rheumatoid arthritis can differ from disease activity assessments and provide an example of hidden symptoms revealed through further probing, along with the impact of therapy adjustments on achieving remission.

A panel of medical experts discuss complications and prognostic factors in uncontrolled rheumatoid arthritis.

A panel of medical experts discuss the prevalence and management of poorly controlled rheumatoid arthritis in clinical practice.

Adjusted analyses reveal a statistically significantly higher prescription medication cost in patients with RA compared to those without.

Results showed comparable clinically meaningful improvements in health-related quality of life among patients treated with the adalimumab reference product and biosimilar adalimumab-adbm.

Results showed particular heavy metals increased the risk of arthritis.

Inverse variance weighting showed beef intake, iron intake, process meat intake, cheese intake, and fresh and dried fruit intake were strongly linked to inflammatory arthritis.

Higher PROs, which were indicative of worse disease activity, were more likely to be reported in the spring and fall months.

Erectile dysfunction was significantly linked to arthritis and remained significant even after adjustment.

Patients with RA had an increased risk of fractures compared with controls, with significant baseline predictors for future fractures identified as higher age, low body mass index, and low bone mineral density.

Factors independently associated with persistently active RA included age, gender, previous or current smoking status, and social deprivation.

A new study shows RA is linked to an increased risk of hematological tumors and bladder, lung, and liver cancer compared to the general population.

Patients with RA and obesity exhibited worse scores for subjective measures like pain and fatigue compared to those without obesity.

RA was linked to an increased risk of ischemic and hemorrhagic strokes, with further analysis revealing sex-based differences in stroke outcomes in men vs women with RA.

A study presented at EULAR 2024 found patients with RA of low socioeconomic status have a high prevalence of fatigue.

Compared to patients on stable TNFi, patients tapering TNFi to withdrawal experienced significantly more flares and had lower Boolean 2.0 remission rates.

Positive personality traits and perceived disease impact may play a larger role in explaining sleep disturbances in patients with RA than disease activity, anxiety, or depression.

Patients with RA had a greater risk of delayed cervical cancer screening, and smoking was associated with a decrease in prostate cancer screening in patients with RA.